 MORRISVILLE, N.C., March 01, 2021 GLOBE NEWSWIRE -- Syneos Health, Inc. Nasdaq: SYNH the Company or Syneos Health, the only fully integrated biopharmaceutical solutions organization combining a CRO Contract Research Organization and a CCO Contract Commercial Organization, today announced it commenced an underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation the Selling Stockholders of an aggregate of 7,000,000 shares of the Companys common stock the Offering pursuant to the Companys shelf registration statement filed with the Securities and Exchange Commission SEC. The Selling Stockholders intend to grant the underwriter a 30-day option to purchase up to 1,050,000 additional shares of common stock. Syneos Health is not selling any shares and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the Offering. 